Swedbank Ab Ionis Pharmaceuticals Inc Transaction History

Swedbank Ab

$77.1 Billion
Q3 2024

A detailed history of Swedbank Ab transactions in Ionis Pharmaceuticals Inc stock. As of the latest transaction made, Swedbank Ab holds 129,373 shares of IONS stock, worth $4.49 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

129,373

Previous 129,373 -0.0%

Holding current value

$4.49 Million

Previous $6.17 Million 15.94%

% of portfolio

0.01%

Previous 0.01%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Jul 18, 2024	SELL	$36.45 - $47.7 $483,618 - $632,883	-13,268 Reduced 9.3%	129,373 $6.17 Million
Q1 2024 May 21, 2024	BUY	$42.03 - $53.55 $6 Million - $7.64 Million	142,641 New	142,641 $6.18 Billion
Q4 2023 Dec 09, 2024	BUY	$43.39 - $51.63 $176,120 - $209,566	4,059 Added 2.96%	140,998 $7.13 Million
Q3 2023 Dec 09, 2024	SELL	$38.5 - $47.13 $30.8 Million - $37.7 Million	-799,809 Reduced 85.38%	136,939 $6.21 Million
Q2 2023 Dec 09, 2024	SELL	$34.73 - $43.33 $865,679 - $1.08 Million	-24,926 Reduced 2.59%	936,748 $38.4 Million
Q1 2023 Dec 09, 2024	SELL	$33.58 - $41.2 $2.01 Million - $2.46 Million	-59,755 Reduced 5.85%	961,674 $34.4 Million
Q3 2022 Dec 09, 2024	SELL	$36.54 - $48.66 $31,132 - $41,458	-852 Reduced 0.08%	1,021,429 $45.2 Million
Q2 2022 Dec 09, 2024	SELL	$31.71 - $43.0 $3.01 Million - $4.09 Million	-95,058 Reduced 8.51%	1,022,281 $37.8 Million
Q3 2021 Dec 09, 2024	BUY	$33.54 - $40.55 $2,146 - $2,595	64 Added 0.01%	1,117,339 $37.5 Million
Q2 2021 Dec 09, 2024	SELL	$34.54 - $47.25 $130,975 - $179,172	-3,792 Reduced 0.34%	1,117,275 $44.6 Million
Q1 2021 Dec 09, 2024	BUY	$42.51 - $63.78 $47.7 Million - $71.5 Million	1,121,067 New	1,121,067 $50.4 Million

Others Institutions Holding IONS

# of Institutions

402

Shares Held

136M

Call Options Held

862K

Put Options Held

582K

View Full List

About IONIS PHARMACEUTICALS INC

Ticker IONS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 141,940,992
Market Cap $4.92B
Description
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for famil...

More about IONS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Swedbank Ab, based on Form 13F filings with the SEC.

News

Stay updated on Swedbank Ab with notifications on news.

Account